bioRxivMicrobiology
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection
B. Beddingfield, N. Iwanaga, P. P. Chapagain, W. Zheng, C. J. Roy, T. Y. Hu, J. Kolls, G. Bix
Abstract
Many efforts to design and screen therapeutics for severe acute respiratory syndrome coronavirus (SARS-CoV-2) have focused on inhibiting viral cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on inhibiting SARS-CoV-2 entry through a hypothesized 5{beta}1 integrin-based mechanism, and indicates that inhibiting the spike protein interaction with 5{beta}1 integrin (+/- ACE2), and the interaction between 5{beta}1 integrin and ACE2 using a molecule ATN-161 represents a promising approach to treat COVID-19.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In-vivo Protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice
A. Narayanappa, E. B. Engler-Chiurazzi, … G. Bix·bioRxiv·May 8, 2021
- Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction
- Integrin activation is an essential component of SARS-CoV-2 infection
P. Simons, D. Rinaldi, … T. Buranda·bioRxiv·Jul 20, 2021
- Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection
C.-k. Oh, T. Nakamura, … S. A. Lipton·bioRxiv·Apr 5, 2022
- Alpha-1 antitrypsin inhibits SARS-CoV-2 infection
L. Wettstein, C. Conzelmann, … J. Muench·bioRxiv·Jul 2, 2020
- Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
D. Bojadzic, O. Alcazar, … P. Buchwald·bioRxiv·Oct 22, 2020